⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 5 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects

Iñigo Landa Caitlin E.M. Thornton Bin Xu Jacob Haase Gnana P. Krishnamoorthy Jingzhu Hao Jeffrey A. Knauf Zachary T. Herbert Paula Martínez Marı́a A. Blasco Ronald Ghossein James A. Fagin

View at Publisher

Ask AI

Bookmark

Share

Key Points

Telomerase upregulation accelerates tumor progression in BrafV600E-driven thyroid cancer, whereas targeted inhibition counteracts disease development.
In vivo treatment combining dabrafenib plus trametinib was administered to mice, suppressing oncogenic signaling and downstream non-telomeric effects.
Findings highlight combined kinase inhibition as a viable strategy against advanced thyroid cancer; mouse model, requiring further preclinical confirmation.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Preclinical study reveals effects of dabrafenib and trametinib on telomerase-driven thyroid cancer in mice, highlighting therapeutic avenues.

Abstract

In vivo dabrafenib plus trametinib treatment of mice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Landa et al. (2024) studied this question.

synapsesocial.com/papers/68e5857ab6db643587522357 https://doi.org/10.1158/1541-7786.27035422

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
2Supplementary Figure 2 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
3Supplementary Figure 2 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
4Supplementary Figure 4 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
5Supplementary Figure 4 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
6Supplementary Figure 1 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
7Supplementary Figure 1 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024
8Supplementary Figure 3 from Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects2024